PG
MRK icon

Prostatis Group’s Merck MRK Stock Holding History

Prostatis Group’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$347K Sell
2,700
-57
-2% -$6.67K 0.08% 132
2026
Q1 		$332K Sell
2,757
-58
-2% -$6.7K 0.08% 128
2025
Q4 		$296K Buy
+2,815
New +$264K 0.07% 138
2025
Q1 		– Sell
-2,773
Closed -$276K – 158
2024
Q4 		$276K Sell
2,773
-693
-20% -$71.4K 0.08% 131
2024
Q3 		$394K Sell
3,466
-105
-3% -$12.5K 0.13% 102
2024
Q2 		$442K Buy
3,571
+677
+23% +$87.2K 0.16% 100
2024
Q1 		$382K Sell
2,894
-167
-5% -$20.6K 0.14% 103
2023
Q4 		$334K Sell
3,061
-296
-9% -$30.7K 0.14% 101
2023
Q3 		$376K Buy
3,357
+333
+11% +$35.9K 0.18% 74
2023
Q2 		$349K Sell
3,024
-5,190
-63% -$589K 0.16% 83
2023
Q1 		$891K Sell
8,214
-31
-0.4% -$3.35K 0.47% 52
2022
Q4 		$915K Buy
8,245
+5,758
+232% +$589K 0.56% 45
2022
Q3 		$214K Buy
2,487
+125
+5% +$11.2K 0.25% 60
2022
Q2 		$215K Buy
+2,362
New +$209K 0.34% 42
2020
Q3 		– Sell
-4,570
Closed -$337K – 79
2020
Q2 		$337K Buy
+4,570
New +$344K 0.68% 42

Other funds holding MRK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Prostatis Group's MRK Position: Q2 2026 in Review

Prostatis Group reduced its Merck (MRK) stake by 2.1% in Q2 2026, selling an estimated $6.67K and leaving 2,700 shares worth $347K. The position accounts for 0.08% of the portfolio, ranked #132.

Prostatis Group first reported a position in MRK in Q2 2020 and has held it in 15 quarters since. The position peaked at $915K in Q4 2022. 3,852 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Prostatis Group held 2,700 shares of Merck worth $347K as of Q2 2026.
  • Prostatis Group sold 57 Merck shares in Q2 2026, an estimated $6.67K.
  • Merck made up 0.08% of Prostatis Group's portfolio in Q2 2026, its #132 holding.
  • Prostatis Group first reported a position in Merck in Q2 2020 and has held it in 15 quarters since.
  • Prostatis Group's Merck position peaked at $915K in Q4 2022.
  • 3,852 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Prostatis Group's 13F filing for Q2 2026, filed 14 Aug 2026.